Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1998 2
1999 3
2000 7
2002 2
2003 3
2004 4
2005 4
2006 4
2007 1
2008 1
2009 2
2011 2
2012 1
2013 2
2014 6
2018 2
2019 3
2020 1
2021 4
2022 2
2023 4
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, Kurtulmus A, Tomlinson A, Mitrova Z, Foti F, Del Giovane C, Quested DJ, Cowen PJ, Barbui C, Amato L, Efthimiou O, Cipriani A. De Crescenzo F, et al. Lancet. 2022 Jul 16;400(10347):170-184. doi: 10.1016/S0140-6736(22)00878-9. Lancet. 2022. PMID: 35843245 Free article.
Benzodiazepines, eszopiclone, zolpidem, and zopiclone were more efficacious than melatonin, ramelteon, and zaleplon (SMD 0.27-0.71 [moderate to very low]). Intermediate-acting benzodiazepines, long-acting benzodiazepines, and eszopiclone had fewer discontinuations due to a …
Benzodiazepines, eszopiclone, zolpidem, and zopiclone were more efficacious than melatonin, ramelteon, and zaleplon (SMD 0.27-0.71 [m …
Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis.
Yue JL, Chang XW, Zheng JW, Shi L, Xiang YJ, Que JY, Yuan K, Deng JH, Teng T, Li YY, Sun W, Sun HQ, Vitiello MV, Tang XD, Zhou XY, Bao YP, Shi J, Lu L. Yue JL, et al. Sleep Med Rev. 2023 Apr;68:101746. doi: 10.1016/j.smrv.2023.101746. Epub 2023 Jan 14. Sleep Med Rev. 2023. PMID: 36701954
Z-drugs were more efficacious than placebo for SL, WASO, TST and SE, but with higher risk to safety. Zaleplon and eszopiclone had better efficacy than placebo for TST and SQ respectively. MRAs may also be efficacious for sleep-onset insomnia with good safety. ...
Z-drugs were more efficacious than placebo for SL, WASO, TST and SE, but with higher risk to safety. Zaleplon and eszopiclone had bet …
Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
McElroy H, O'Leary B, Adena M, Campbell R, Monfared AAT, Meier G. McElroy H, et al. J Manag Care Spec Pharm. 2021 Sep;27(9):1296-1308. doi: 10.18553/jmcp.2021.21011. Epub 2021 Jun 12. J Manag Care Spec Pharm. 2021. PMID: 34121443 Free PMC article.
Interventions of interest were specified as lemborexant, suvorexant, benzodiazepines, benzodiazepine receptor agonists (also called Z-drugs [zolpidem, eszopiclone, zaleplon, zopiclone]), trazodone, and ramelteon. Efficacy outcomes included wake after sleep onset (WASO), sl …
Interventions of interest were specified as lemborexant, suvorexant, benzodiazepines, benzodiazepine receptor agonists (also called Z-drugs …
Zaleplon pharmacokinetics and absolute bioavailability.
Rosen AS, Fournié P, Darwish M, Danjou P, Troy SM. Rosen AS, et al. Biopharm Drug Dispos. 1999 Apr;20(3):171-5. doi: 10.1002/(sici)1099-081x(199904)20:3<171::aid-bdd169>3.0.co;2-k. Biopharm Drug Dispos. 1999. PMID: 10211871 Clinical Trial.
Subjects received 1 and 2.5 mg intravenous (i.v.) infusions of zaleplon during the first and second periods, respectively, and then were randomly assigned to receive a 5 mg oral dose or 5 mg i.v. infusion of zaleplon in a crossover design during the final two period …
Subjects received 1 and 2.5 mg intravenous (i.v.) infusions of zaleplon during the first and second periods, respectively, and then w …
Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem.
Joya FL, Kripke DF, Loving RT, Dawson A, Kline LE. Joya FL, et al. J Clin Sleep Med. 2009 Aug 15;5(4):377-83. J Clin Sleep Med. 2009. PMID: 19968019 Free PMC article. Review.
Parallel controlled clinical trials of eszopiclone, ramelteon, zaleplon, and zolpidem were included when data on subjects, duration of exposure, and adverse effects were available. ...There were insufficient data concerning individual studies of zaleplon and ramelte …
Parallel controlled clinical trials of eszopiclone, ramelteon, zaleplon, and zolpidem were included when data on subjects, duration o …
The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis.
Stranks EK, Crowe SF. Stranks EK, et al. J Clin Exp Neuropsychol. 2014;36(7):691-700. doi: 10.1080/13803395.2014.928268. Epub 2014 Jun 16. J Clin Exp Neuropsychol. 2014. PMID: 24931450
The "z-drugs" zopiclone, zolpidem, eszopiclone, and zaleplon were introduced in the 1980s for the treatment of insomnia, as it was observed that the side effect profile associated with these medications were more benign than those related to the benzodiazepines. ...However …
The "z-drugs" zopiclone, zolpidem, eszopiclone, and zaleplon were introduced in the 1980s for the treatment of insomnia, as it was ob …
Single-Cell Meta-Analysis of Neutrophil Activation in Kawasaki Disease and Multisystem Inflammatory Syndrome in Children Reveals Potential Shared Immunological Drivers.
Beltran JVB, Lin FP, Chang CL, Ko TM. Beltran JVB, et al. Circulation. 2023 Nov 28;148(22):1778-1796. doi: 10.1161/CIRCULATIONAHA.123.064734. Epub 2023 Oct 31. Circulation. 2023. PMID: 37905415
Last, we identified and validated TSPO (translocator protein) and S100A12 (S100 calcium-binding protein A12) as main molecular targets, for which the Food and Drug Administration-approved drugs methotrexate, zaleplon, metronidazole, lorazepam, clonazepam, temazepam, and zo …
Last, we identified and validated TSPO (translocator protein) and S100A12 (S100 calcium-binding protein A12) as main molecular targets, for …
Absence of an interaction between ibuprofen and zaleplon.
Sanchez Garcia P, Carcas A, Zapater P, Rosendo J, Paty I, Leister CA, Troy SM. Sanchez Garcia P, et al. Am J Health Syst Pharm. 2000 Jun 15;57(12):1137-41. Am J Health Syst Pharm. 2000. PMID: 10911512 Clinical Trial.
The potential interaction between zaleplon and ibuprofen was studied. Healthy adult volunteers were given a dose of zaleplon 10 mg alone, a dose of ibuprofen 600 mg alone, or a dose of zaleplon 10 mg and a dose of ibuprofen 600 mg concomitantly in an open-lab …
The potential interaction between zaleplon and ibuprofen was studied. Healthy adult volunteers were given a dose of zaleplon 1 …
Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.
Greenblatt DJ, Harmatz JS, von Moltke LL, Ehrenberg BL, Harrel L, Corbett K, Counihan M, Graf JA, Darwish M, Mertzanis P, Martin PT, Cevallos WH, Shader RI. Greenblatt DJ, et al. Clin Pharmacol Ther. 1998 Nov;64(5):553-61. doi: 10.1016/S0009-9236(98)90139-4. Clin Pharmacol Ther. 1998. PMID: 9834048 Clinical Trial.

The overall order of agonist potency was as follows: placebo < 10 mg zaleplon < 20 mg zaleplon < 10 mg zolpidem < 20 mg zolpidem; on a number of measures, 20 mg zaleplon was comparable to 10 mg zolpidem. ...CONCLUSIONS: Benzodiazepine agonist effe

…

The overall order of agonist potency was as follows: placebo < 10 mg zaleplon < 20 mg zaleplon < 10 mg zolpidem <

…
Effects of zolpidem and zaleplon on cognitive performance after emergent morning awakenings at Tmax: a randomized placebo-controlled trial.
Dinges DF, Basner M, Ecker AJ, Baskin P, Johnston SL. Dinges DF, et al. Sleep. 2019 Mar 1;42(3):zsy258. doi: 10.1093/sleep/zsy258. Sleep. 2019. PMID: 30576525 Clinical Trial.
To evaluate the risk to operational safety, a ground-based, double-blind, placebo-controlled study on the emergent awakening effects of zolpidem and zaleplon was conducted. METHODS: N = 34 participants (age M = 42.1 9.7; 25 males; 9 Astronauts, 7 Astronaut candidates, an …
To evaluate the risk to operational safety, a ground-based, double-blind, placebo-controlled study on the emergent awakening effects of zolp …
62 results